高危前列腺癌患者的新治疗方法：2014年美国泌尿外科学会年会关键研究总结
Novel approaches in the high-risk prostate cancer patient: Summary of key research presented at AUA 2014.
出版信息
Can Urol Assoc J. 2014 Jul;8(7-8 Suppl 4):S137. doi: 10.5489/cuaj.2285.
Abstract
Another topic of focus at AUA 2014 was the subgroup of prostate cancer patients deemed to be at high risk.
摘要
2014年美国泌尿外科学会年会的另一个重点议题是被认为处于高风险的前列腺癌患者亚组。
相似文献
1
Novel approaches in the high-risk prostate cancer patient: Summary of key research presented at AUA 2014.高危前列腺癌患者的新治疗方法：2014年美国泌尿外科学会年会关键研究总结
Can Urol Assoc J. 2014 Jul;8(7-8 Suppl 4):S137. doi: 10.5489/cuaj.2285.
2
Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer.美国泌尿外科学会（AUA）尿症状评分与局限性前列腺癌男性患者疾病分期之间的关联。
Urol Oncol. 2002 Mar-Apr;7(2):73-6. doi: 10.1016/s1078-1439(01)00155-7.
3
Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.立体定向体部放射治疗前列腺癌后晚期尿症状加重的临床特征和处理。
Front Oncol. 2014 May 26;4:122. doi: 10.3389/fonc.2014.00122. eCollection 2014.
4
I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial.I-125与Pd-103治疗低风险前列腺癌：一项前瞻性随机多中心试验的发病结果
Cancer J. 2002 Jan-Feb;8(1):67-73. doi: 10.1097/00130404-200201000-00012.
5
American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.美国泌尿外科学会 (AUA) 前列腺癌检测指南：流程和原理。
BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318.
6
Prophylactic urethral stenting with Memokath 028SW in prostate cancer patients undergoing prostate I seed implants: phase I/II study.在接受前列腺碘籽植入的前列腺癌患者中使用Memokath 028SW进行预防性尿道支架置入：I/II期研究。
J Contemp Brachytherapy. 2011 Mar;3(1):18-22. doi: 10.5114/jcb.2011.21038. Epub 2011 Mar 31.
7
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.晚期前列腺癌：AUA/ASTRO/SUO 指南第二部分。
J Urol. 2021 Jan;205(1):22-29. doi: 10.1097/JU.0000000000001376. Epub 2020 Sep 22.
8
[Prostate cancer: the essential from the congress of the American Urological Association (AUA) 2005].
Ann Urol (Paris). 2005 Oct;39 Suppl 4:S89-101.
9
10
A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.一项两阶段全基因组关联研究，旨在确定与前列腺癌放射治疗后尿症状发展相关的单核苷酸多态性。
J Urol. 2013 Jul;190(1):102-8. doi: 10.1016/j.juro.2013.01.096. Epub 2013 Feb 1.
本文引用的文献
1
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.局部晚期前列腺癌的短期新辅助雄激素剥夺疗法与外照射放疗：RTOG 8610的长期结果
J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.
2
3
4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.T2-3N0M0期前列腺癌根治性前列腺切除术前行新辅助激素治疗的欧洲前瞻性随机研究的4年随访结果。欧洲前列腺癌新辅助治疗研究组
Eur Urol. 2000 Dec;38(6):706-13. doi: 10.1159/000020366.
4
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.根治性前列腺切除术前行新辅助雄激素剥夺治疗的CUOG随机试验：治疗后36个月的前列腺特异性抗原结果。加拿大泌尿外科肿瘤学组
Urology. 1999 Apr;53(4):757-63. doi: 10.1016/s0090-4295(98)00616-5.
5
Hormonal treatment before radical prostatectomy: a 3-year followup.前列腺癌根治术前的激素治疗：3年随访
J Urol. 1998 Jun;159(6):2013-6; discussion 2016-7. doi: 10.1016/S0022-5347(01)63230-0.
Zotero 插件